WHO ICTRP trial
An exploratory, single-arm phase II clinical study of envolimab in the…
ChiCTR2100046990 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100046990 |
|---|---|
| Public title | An exploratory, single-arm phase II clinical study of envolimab in the first-line treatment of advanced NSCLC with PD-L1 overexpression in the elderly |
| Scientific title | An exploratory, single-arm phase II clinical study of envolimab in the first-line treatment of advanced NSCLC with PD-L1 overexpression in the elderly |
| Primary sponsor | The First Affiliated Hospital of Xiamen University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | non-small cell lung cancer |
| Interventions | Experimental Group:Envolizumab first-line treatment |
| Registration date | Jun 6, 2021 |
| Target size | Experimental Group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: